111 related articles for article (PubMed ID: 1880935)
1. [In vivo and in vitro antifungal activity of fluconazole].
Kawasaki K; Matsumura Y; Ogawa M; Tsuji A; Matsunaga T; Goto S
Jpn J Antibiot; 1991 May; 44(5):552-61. PubMed ID: 1880935
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activity of fluconazole, a novel bistriazole antifungal agent].
Yamaguchi H; Uchida K; Kawasaki K; Matsunaga T
Jpn J Antibiot; 1989 Jan; 42(1):1-16. PubMed ID: 2540356
[TBL] [Abstract][Full Text] [Related]
3. Azole resistance in Candida albicans.
Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
[TBL] [Abstract][Full Text] [Related]
4. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.
Hughes CE; Bennett RL; Tuna IC; Beggs WH
Antimicrob Agents Chemother; 1988 Feb; 32(2):209-12. PubMed ID: 2834995
[TBL] [Abstract][Full Text] [Related]
5. T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.
Yotsuji A; Shimizu K; Araki H; Fujimaki K; Nishida N; Hori R; Annen N; Yamamoto S; Hayakawa H; Imaizumi H; Watanbe Y; Narita H
Antimicrob Agents Chemother; 1997 Jan; 41(1):30-4. PubMed ID: 8980750
[TBL] [Abstract][Full Text] [Related]
6. A comparison of miconazole, ketoconazole and fluconazole in their effects on temperature-dependent growth and thermal death in Candida albicans.
Madeira-Lopes A; Miranda J
J Med Vet Mycol; 1995; 33(6):375-8. PubMed ID: 8683405
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
8. Effect of ketoconazole, itraconazole and fluconazole on the gastrointestinal colonization of mice by Candida albicans.
Samonis G; Maraki S; Hajiioannou I; Chatzinikolaou I; Rolston KV; Bodey GP; Kontoyiannis DP
J Chemother; 2001 Feb; 13(1):66-9. PubMed ID: 11233803
[TBL] [Abstract][Full Text] [Related]
9. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole.
Rautemaa R; Richardson M; Pfaller M; Perheentupa J; Saxen H
Scand J Infect Dis; 2008; 40(11-12):904-7. PubMed ID: 18651265
[TBL] [Abstract][Full Text] [Related]
10. The triazole antifungal agents: a review of itraconazole and fluconazole.
Bailey EM; Krakovsky DJ; Rybak MJ
Pharmacotherapy; 1990; 10(2):146-53. PubMed ID: 2161523
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
12. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole.
Ohtsuka K; Watanabe M; Orikasa Y; Inouye S; Uchida K; Yamaguchi H; Kondo S; Takeuchi T
J Antimicrob Chemother; 1997 Jan; 39(1):71-7. PubMed ID: 9044030
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole therapy of oropharyngeal candidiasis in a patient with multiple endocrine failure does not correlate with Candida albicans susceptibility to fluconazole in vitro.
Field EA; Millns B; Pearce PK; Martin MV; Parkinson T; Hitchcock CA
J Med Vet Mycol; 1996; 34(3):205-8. PubMed ID: 8803802
[TBL] [Abstract][Full Text] [Related]
14. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis.
Force RW; Nahata MC
Ann Pharmacother; 1995 Jan; 29(1):10-5. PubMed ID: 7711339
[TBL] [Abstract][Full Text] [Related]
15. Comparison between efficacy of allicin and fluconazole against Candida albicans in vitro and in a systemic candidiasis mouse model.
Khodavandi A; Alizadeh F; Harmal NS; Sidik SM; Othman F; Sekawi Z; Jahromi MA; Ng KP; Chong PP
FEMS Microbiol Lett; 2011 Feb; 315(2):87-93. PubMed ID: 21204918
[TBL] [Abstract][Full Text] [Related]
16. Activity of fluconazole against Candida albicans isolates from HIV+ patients in a digestive candidosis turkey model.
Reynes J; Mallie M; Ravisse P; Bastide JM
J Med Vet Mycol; 1992; 30(5):363-7. PubMed ID: 1469537
[TBL] [Abstract][Full Text] [Related]
17. Antifungal activity of D0870 against murine infections and its mechanism of action.
Yamada H; Tsuda T; Watanabe T; Kusakabe S; Mochizuki H
Chemotherapy; 1998; 44(2):112-20. PubMed ID: 9551242
[TBL] [Abstract][Full Text] [Related]
18. Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.
Wang Y; Jia XM; Jia JH; Li MB; Cao YY; Gao PH; Liao WQ; Cao YB; Jiang YY
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):e40-6. PubMed ID: 19413603
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Khan MA; Khan A; Owais M
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
